Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

被引：34

作者：

Skoulidis, Ferdinandos ^{[1
]}

Papadimitrakopoulou, Vassiliki A. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

来源：

CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 03期

关键词：

ACQUIRED-RESISTANCE; EGFR INHIBITORS; AZD9291; AFATINIB; GEFITINIB; TKI;

D O I：

10.1158/1078-0432.CCR-15-2815

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy. Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It received breakthrough therapy designation, priority review status, and accelerated approval from the FDA. (C) 2016 AACR.

引用

页码：618 / 622

页数：5

共 29 条

[1]

[Anonymous], P 16 WORLD C LUNG CA

[2]

[Anonymous], P 16 WORLD C LUNG CA

[3]

[Anonymous], ASCO M

[4]

[Anonymous], P ELCC 2016 EUR LUNG

[5]

[Anonymous], TAGRISSO OS TABL OR

[6]

[Anonymous], P 16 WORLD C LUNG CA

[7] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].

Cross, Darren A. E. ;

Ashton, Susan E. ;

Ghiorghiu, Serban ;

Eberlein, Cath ;

Nebhan, Caroline A. ;

Spitzler, Paula J. ;

Orme, Jonathon P. ;

Finlay, M. Raymond V. ;

Ward, Richard A. ;

Mellor, Martine J. ;

Hughes, Gareth ;

Rahi, Amar ;

Jacobs, Vivien N. ;

Brewer, Monica Red ;

Ichihara, Eiki ;

Sun, Jing ;

Jin, Hailing ;

Ballard, Peter ;

Al-Kadhimi, Katherine ;

Rowlinson, Rachel ;

Klinowska, Teresa ;

Richmond, Graham H. P. ;

Cantarini, Mireille ;

Kim, Dong-Wan ;

Ranson, Malcolm R. ;

Pao, William .

CANCER DISCOVERY, 2014, 4 (09) :1046-1061

[8] Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models [J].

Eberlein, Catherine A. ;

Stetson, Daniel ;

Markovets, Aleksandra A. ;

Al-Kadhimi, Katherine J. ;

Lai, Zhongwu ;

Fisher, Paul R. ;

Meador, Catherine B. ;

Spitzler, Paula ;

Ichihara, Eiki ;

Ross, Sarah J. ;

Ahdesmaki, Miika J. ;

Ahmed, Ambar ;

Ratcliffe, Laura E. ;

O'Brien, Elizabeth L. Christey ;

Barnes, Claire H. ;

Brown, Henry ;

Smith, Paul D. ;

Dry, Jonathan R. ;

Beran, Garry ;

Thress, Kenneth S. ;

Dougherty, Brian ;

Pao, William ;

Cross, Darren A. E. .

CANCER RESEARCH, 2015, 75 (12) :2489-2500

[9] Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition [J].

Hata, Aaron N. ;

Niederst, Matthew J. ;

Archibald, Hannah L. ;

Gomez-Caraballo, Maria ;

Siddiqui, Faria M. ;

Mulvey, Hillary E. ;

Maruvka, Yosef E. ;

Ji, Fei ;

Bhang, Hyo-eun C. ;

Radhakrishna, Viveksagar Krishnamurthy ;

Siravegna, Giulia ;

Hu, Haichuan ;

Raoof, Sana ;

Lockerman, Elizabeth ;

Kalsy, Anuj ;

Lee, Dana ;

Keating, Celina L. ;

Ruddy, David A. ;

Damon, Leah J. ;

Crystal, Adam S. ;

Costa, Carlotta ;

Piotrowska, Zofia ;

Bardelli, Alberto ;

Iafrate, Anthony J. ;

Sadreyev, Ruslan I. ;

Stegmeier, Frank ;

Getz, Gad ;

Sequist, Lecia V. ;

Faber, Anthony C. ;

Engelman, Jeffrey A. .

NATURE MEDICINE, 2016, 22 (03) :262-269

[10] AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer [J].

Jaenne, Pasi A. ;

Yang, James Chih-Hsin ;

Kim, Dong-Wan ;

Planchard, David ;

Ohe, Yuichiro ;

Ramalingam, Suresh S. ;

Ahn, Myung-Ju ;

Kim, Sang-We ;

Su, Wu-Chou ;

Horn, Leora ;

Haggstrom, Daniel ;

Felip, Enriqueta ;

Kim, Joo-Hang ;

Frewer, Paul ;

Cantarini, Mireille ;

Brown, Kathryn H. ;

Dickinson, Paul A. ;

Ghiorghiu, Serban ;

Ranson, Malcolm .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) :1689-1699

← 1 2 3 →